Vaxcyte (PCVX) Climbs +18% Over 30 Days on Pipeline Updates and Index Inclusion
Key Takeaways
- Vaxcyte (PCVX) climbed approximately +18% over the last 30 days, rising from $47.46 to $56.21 as of July 14, 2026.
- The rally was fueled by a VAX-A1 Phase 1 clinical trial update for the company's Group A Strep vaccine candidate and broad-based analyst reaffirmations.
- Inclusion in major Russell growth indexes during the late-June rebalancing window amplified institutional visibility and passive fund flows.
- Wall Street consensus remains strongly bullish, with price targets ranging from $67 to $163 and a median target above $100.
- The stock rebounded sharply from early-June lows near $45, recovering all post-earnings losses from the May Q1 2026 results miss.
Vaxcyte (PCVX) Company Overview and Pipeline Focus
Vaxcyte, Inc. is a clinical-stage vaccine innovation company headquartered in San Carlos, California, focused on engineering high-fidelity conjugate and novel protein vaccines to prevent serious bacterial infectious diseases. The company's lead program centers on pneumococcal conjugate vaccines (PCVs), with VAX-31 — a 31-valent PCV candidate — currently in the OPUS Phase 3 adult clinical program and a Phase 2 infant study. This positions VAX-31 as the broadest-spectrum PCV candidate in clinical development today. Vaxcyte also advances VAX-24, a 24-valent PCV candidate, and VAX-XL, an earlier-stage program designed to further expand serotype coverage.
Beyond pneumococcal disease, Vaxcyte is expanding its pipeline with VAX-A1, a prophylactic vaccine candidate targeting Group A Streptococcus (GAS) infections, and VAX-GI, targeting Shigella. The company's proprietary XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma (STRO), enables efficient manufacturing of complex protein antigens. With approximately 97% institutional ownership and a market capitalization near $8.4 billion, Vaxcyte is closely watched by biotech investors seeking exposure to the next generation of preventive vaccines.
PCVX Stock Performance Over the Past 30 Days and Quarter
Over the past 30 calendar days, PCVX delivered a gain of roughly +18.4%, climbing from a closing price of $47.46 on June 12, 2026, to $56.21 on July 14, 2026. The upward move accelerated in late June and early July, with the stock breaking above its 50-day moving average near $52 and reaching an intra-month high of $60.67 on July 7. The rally marked a sharp reversal from mid-June, when the stock had touched levels around $45.31 — its lowest point since April 2026.
Looking at the broader quarterly picture, PCVX experienced significant volatility. The stock began the second quarter under pressure following the May 6 Q1 2026 earnings release, where the company reported a net loss of $2.30 per share, missing consensus estimates of $1.74. Shares declined from the low $50s in mid-May to the mid-$45 range by early June, representing a drawdown of roughly 14% from late-April levels. The subsequent recovery, driven by pipeline catalysts and index-driven demand, brought the stock back into positive territory on a quarterly basis. As of mid-July, PCVX had erased its post-earnings losses and was trading approximately 7% above mid-May levels.
Drivers Behind the Recent 30-Day Rally in PCVX
The most significant near-term catalyst was the June 16 clinical update on VAX-A1, Vaxcyte's early-stage vaccine candidate targeting Group A Strep infections. The company confirmed that the Phase 1 study is evaluating safety, tolerability, and immunogenicity across three dose levels in healthy young adults. Investors responded favorably to the update, viewing it as a validation of Vaxcyte's ability to expand its pipeline beyond pneumococcal vaccines into another large infectious disease market with significant unmet need.
On June 18, Mizuho Securities analyst Salim Syed reiterated a Buy rating with a $163 price target — representing nearly 190% upside from levels at the time — reinforcing bullish sentiment. Needham also maintained its Buy rating and $110 target on June 26. The cumulative effect of multiple analyst reaffirmations throughout the period created a supportive backdrop for institutional accumulation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The late-June Russell index rebalancing proved to be another powerful tailwind. Vaxcyte's inclusion in several Russell growth and small-cap benchmarks triggered passive fund buying and elevated the stock's profile among index-tracking institutional investors. Trading volume surged above 8.6 million shares on June 26, well above the daily average of approximately 1.8 million, reflecting index-driven repositioning. Additionally, 13F filings showed continued institutional interest, with firms such as Candriam S.C.A. and Royal Bank of Canada increasing their positions during the first and second quarters.
Quarterly Performance Context and Recovery Path
The quarterly narrative was defined by a post-earnings reset followed by a pipeline-driven recovery. Vaxcyte's Q1 2026 results, reported on May 6, showed a GAAP net loss of $320.6 million — significantly wider than the $140.7 million loss in the same quarter a year earlier — driven by escalating R&D and manufacturing costs associated with the advancing VAX-31 Phase 3 program. The earnings miss and widening losses triggered a sell-off that persisted through early June.
However, the downward pressure proved temporary as attention shifted back to the company's clinical catalysts. The VAX-A1 update, combined with the company's June 15 annual meeting — where all board proposals passed with overwhelming shareholder support — restored confidence in management's execution. Guggenheim's June 3 reiteration of its Buy rating and $116 price target also helped stabilize sentiment. The Russell index inclusion in late June delivered the final push, converting what had been a negative quarter into a net positive as institutional flows accelerated into July. The quarterly pattern underscored how heavily PCVX trades on pipeline milestones and institutional positioning rather than near-term financial metrics.
Exploring AI-Powered Trading Strategies for Stocks Like PCVX
For investors seeking a data-driven approach to navigating stocks like PCVX, Tickeron's Trending AI Robots page offers a curated view into the platform's most relevant algorithmic trading strategies. Tickeron hosts hundreds of AI-powered trading bots that analyze thousands of tickers across multiple timeframes and market conditions, but only the top-performing and most contextually relevant bots are featured in this section. These bots employ diverse strategies — from swing trading and trend following to pattern recognition and momentum-based models — each with transparent performance metrics and track records. For traders who prefer systematic, emotion-free decision-making, the Trending AI Robots section provides an accessible entry point to explore how artificial intelligence can complement fundamental research in today's dynamic market environment. I find this resource particularly useful when cross-checking momentum signals alongside clinical and index-driven developments.
Key Drivers to Watch for PCVX Going Forward
The most consequential upcoming event for PCVX is the next quarterly earnings report, expected around August 5, 2026. Analysts forecast a Q2 2026 EPS loss of approximately $1.47, with full-year 2026 EPS estimates at -$7.91. Investors will closely monitor cash burn rates, R&D expenditure trends, and management's updated guidance on the VAX-31 OPUS Phase 3 timeline. The OPUS-1 adult study readout remains the single most important binary catalyst for the stock over the medium term, as positive data could position VAX-31 for regulatory submission and fundamentally de-risk the entire PCV franchise.
Additionally, Vaxcyte's participation in the Leerink Partners Therapeutics Forum (July 14–15) and the BTIG Virtual Biotechnology Conference (July 28–29) may yield incremental pipeline updates and fresh analyst commentary. Broader macro considerations — including Federal Reserve policy, biotech sector sentiment, and M&A activity in the vaccine space — will also influence PCVX's trajectory. On the competitive front, investors should monitor developments from larger vaccine players such as Pfizer (PFE) and GSK (GSK), whose established PCV franchises represent both the competitive benchmark and potential partnership or acquisition landscape for Vaxcyte.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PCVX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PCVX turned positive on August 06, 2026. Looking at past instances where PCVX's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on PCVX as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PCVX moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PCVX broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PCVX entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.378) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.692).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology
Advertisement